Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEPTUNIA
NCT05650567Phase 2Terminated
- Sponsor
- EMD Serono
- Start
- Jan 2023
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 2 trial of enpatoran in dermatomyositis (DM), polymyositis (PM), sponsored by EMD Serono. Started Jan 2023; status: terminated.
02
Drugs
enpatoran
03
Conditions
dermatomyositis (DM)polymyositis (PM)
Beyond the preview
Go deeper on NCT05650567.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05650567.